Stock CYTK CYTOKINETICS, INCORPORATED
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Cytokinetics, Incorporated

Equities

CYTK

US23282W6057

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-06 pm EDT 		5-day change 1st Jan Change
52.26 USD -4.25% Intraday chart for Cytokinetics, Incorporated +6.39% -37.41%
Jun. 05 Sector Update: Health Care Stocks Advance Late Afternoon MT
Jun. 05 Sector Update: Health Care Stocks Rise Wednesday Afternoon MT

Evolution of the average Target Price on Cytokinetics, Incorporated

Price target over the last 5 years

History of analyst recommendation changes

4f9234eb37319db2e8126d0f354b7f.vaaGFtS3Zt-ItjW9TTp1SG0RKcX7NSprveFrNiRhz1w.ysrwToLeDOrC2EP4OEgROVxWc6bCYR8N2L4HZnQ5omzk4s91i48Lq8CDfA~9b5fff402f27b19d8995dba32cf0c0af

Analyst Recommendations on Cytokinetics, Incorporated

B. Riley Cuts Price Target on Cytokinetics to $92 From $122, Maintains Buy Rating MT
Cytokinetics Insider Sold Shares Worth $635,978, According to a Recent SEC Filing MT
Truist Securities Lowers Price Target on Cytokinetics to $70 From $86, Maintains Buy Rating MT
JMP Securities Adjusts Cytokinetics Price Target to $78 From $106, Maintains Market Outperform Rating MT
Raymond James Adjusts Price Target on Cytokinetics to $70 From $92, Maintains Outperform Rating MT
Needham Adjusts Price Target on Cytokinetics to $72 From $108, Maintains Buy Rating MT
Cytokinetics Plans $500 Million Common Stock Offering -- Shares Drop After Hours MT
Oppenheimer Adjusts Cytokinetics Price Target to $106 From $107, Maintains Outperform Rating MT
Cytokinetics Insider Sold Shares Worth $1,012,265, According to a Recent SEC Filing MT
Cytokinetics Insider Sold Shares Worth $2,422,918, According to a Recent SEC Filing MT
Mizuho Securities Adjusts Price Target on Cytokinetics to $99 From $103, Maintains Buy Rating MT
UBS Downgrades Cytokinetics to Neutral From Buy, Adjusts Price Target to $92 From $61 MT
Mizuho Securities Boosts Price Target on Cytokinetics to $103 From $80, Keeps Buy Rating MT
B. Riley Raises Cytokinetics' PT to $122 From $66, Keeps Buy Rating; Notes Heightened Conviction in Aficamten Taking Dominant Market Share Cardiac Myosin Inhibitor Market MT
Truist Securities Raises Cytokinetics' Price Target to $86 From $60, Buy Rating Kept MT
Needham Raises Cytokinetics' Price Target to $108 From $60, Keeps Buy Rating MT
HC Wainwright Raises Cytokinetics Price Target to $94 From $58, Maintains Buy Rating MT
Cantor Fitzgerald Raises Cytokinetics Price Target to $101 From $65, Maintains Overweight Rating MT
Goldman Sachs Starts Coverage on Cytokinetics with Buy Rating, $50 Price Target MT
B. Riley Initiates Cytokinetics With Buy Rating, $66 PT; Says Aficamten's Differentiation Remains Underappreciated MT
UBS Trims Cytokinetics' Price Target to $61 From $62, Keeps Buy Rating MT
HC Wainwright Adjusts Cytokinetics Price Target to $58 From $49, Maintains Buy Rating MT
Cantor Fitzgerald Adjusts Cytokinetics' Price Target to $65 From $59, Keeps Overweight Rating MT
SVB Initiates Cytokinetics at Outperform MT
JPMorgan Raises Cytokinetics' Price Target to $54 From $52, Maintains Overweight Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
54.58 USD
Average target price
83.35 USD
Spread / Average Target
+52.72%
High Price Target
107 USD
Spread / Highest target
+96.04%
Low Price Target
60 USD
Spread / Lowest Target
+9.93%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Cytokinetics, Incorporated

B. Riley
Truist Securities
JMP Securities
Raymond James
Needham & Co.
Oppenheimer
Mizuho Securities
UBS
Cantor Fitzgerald
HC Wainwright
Goldman Sachs
SVB Securities LLC
JPMorgan Chase
BofA Securities
Morgan Stanley
Piper Sandler
Jefferies & Co.
Barclays
Wolfe Research

Ratings for Cytokinetics, Incorporated

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. CYTK Stock
  4. Consensus Cytokinetics, Incorporated